Azacitidine (Azacitidine) Patent Expiration, LOE Window & CMS Spending

Azacitidine (Azacitidine) by Teva Pharmaceuticals: Off-Patent Genericized (AB Competition), 16 AB generics, $4.4M 2024 CMS Part D & Medicaid spend, and $100 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN208216 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$4.4M
2024 Medicare Part D Spend$3.1M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($100 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.